Benchmark restated their speculative buy rating on shares of Nephros (NASDAQ:NEPH – Free Report) in a research note released on Tuesday morning, MarketBeat reports. They currently have a $5.00 target price on the stock.
Nephros Trading Down 3.8 %
Shares of NASDAQ:NEPH traded down $0.06 on Tuesday, reaching $1.52. 1,063 shares of the company traded hands, compared to its average volume of 14,979. The stock has a market capitalization of $16.03 million, a P/E ratio of -16.89 and a beta of 1.19. Nephros has a 52 week low of $1.36 and a 52 week high of $4.04. The business’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.93.
Hedge Funds Weigh In On Nephros
An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP purchased a new position in Nephros, Inc. (NASDAQ:NEPH – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned approximately 0.17% of Nephros at the end of the most recent reporting period. Institutional investors own 41.10% of the company’s stock.
Nephros Company Profile
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
See Also
- Five stocks we like better than Nephros
- Why Invest in 5G? How to Invest in 5G Stocks
- Top-Performing Non-Leveraged ETFs This Year
- How to Invest in Blue Chip Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Following Congress Stock Trades
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.